Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 5:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 57 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Normal saline (1000 mL) Clear all

Conditions: Postpartum Hemorrhage
Interventions: Sublingual Misoprostol, IV Oxytocin; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,358 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Lassa Fever
Interventions: LASSARAB+ aPHAD-SEat 700rU, HDCV Comparator, Normal Saline Placebo, LASSARAB+ aPHAD-SEat 1400rU; Biological · Other
Lead sponsor: Wilbur Chen, MD, MS; Other
Eligibility: 18 Years to 50 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Ovarian Failure, Perimenopausal Disorder, Hormone Disturbance
Interventions: lipoaspiration harvest tSVF, Platelet Rich Plasma, Endovaginal Ultrasound, Cellular Isolation cSVF, Normal Saline (NS) .9% 10 mL Injection, emulsification tSVF; Procedure · Device · Drug
Lead sponsor: Black Tie Medical, Inc.; Industry
Eligibility: 35 Years to 60 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Colchester, Vermont

Conditions: Prosthetic Joint Infection, Vancomycin, Joint Diseases
Interventions: Experimental Intraosseous vancomycin 500mg in 250 mL NS, Standard IV administration of vancomycin; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 19 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer, Breast Neoplasm
Interventions: Docetaxel - Dose A, Anastrozole, cyclophosphamide, Docetaxel - Dose B, Doxorubicin hydrochloride, Tamoxifen Citrate, Capecitabine - Dose B, Capecitabine - Dose A; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Delayed Graft Function
Interventions: Furosemide, Placebo; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Neonatal Encephalopathy, Birth Asphyxia
Interventions: Normal saline placebo, Erythropoietin; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: Up to 24 Hours
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 23
States / cities: Los Angeles, California • Palo Alto, California • San Francisco, California + 15 more

Conditions: Morbid Obesity
Interventions: IV acetaminophen, IV normal saline; Drug
Lead sponsor: McLaren Regional Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Flint, Michigan

Conditions: Glomerulonephritis, Membranous
Interventions: Belimumab 10 mg, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: St Louis, Missouri • Chapel Hill, North Carolina

Conditions: Hemorrhage
Interventions: Oxytocin + normal saline, Normal saline; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 55 Years · Female only
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Video-Assisted Thoracic Surgery, Video-Assisted Thoracoscopic Surgery
Interventions: Normal Saline, Ropivacaine, Epinephrine, Dexamethasone; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 85 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Acute Bronchiolitis
Interventions: Hypertonic saline and epinephrine, Normal saline and epinephrine; Drug
Lead sponsor: Le Bonheur Children's Hospital; Other
Eligibility: 6 Weeks to 2 Years
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Atopic Asthma, Healthy
Interventions: House Dust Mite, Diluent; Biological
Lead sponsor: John Sundy; Other
Eligibility: 18 Years to 40 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: PD Effects of GS-0976 (NDI-010976) on Fractional DNL
Interventions: GS-0976, Placebo, 1-13C acetate, Fructose solution; Drug · Other
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Migraine Headache
Interventions: Normal saline (1000 mL), Control; Other
Lead sponsor: Cooper Norcross Health; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: AL Amyloidosis
Interventions: CAEL-101, SoC: cyclophosphamide, bortezomib, and Dexamethasone (CyBorD), Daratumumab; Drug
Lead sponsor: Alexion Pharmaceuticals, Inc.; Industry
Eligibility: Not listed
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Stanford, California • Detroit, Michigan • Cleveland, Ohio

Conditions: Intrahepatic Cholangiocarcinoma
Interventions: Cisplatin-gemcitabine, Radiation: SIRT + chemotherapy (cisplatin-gemcitabine); Drug · Device
Lead sponsor: Sirtex Medical; Industry
Eligibility: 18 Years and older
Enrollment: 89 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Spokane, Washington

Conditions: Graft-Versus-Host Disease
Interventions: Pentostatin; Drug
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2013
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Obesity, Leptin Resistance
Interventions: Saline, Intralipid, Water, oral fat, Heparin; Drug · Dietary Supplement
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Head and Neck Neoplasms
Interventions: pemetrexed, cisplatin, placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 795 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 15
States / cities: Orange, California • Orlando, Florida • St. Petersburg, Florida + 12 more

Conditions: Post Operative Pain
Interventions: Maxigesic IV, IV Acetaminophen, IV Ibuprofen, Placebo IV; Drug
Lead sponsor: AFT Pharmaceuticals, Ltd.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 276 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Pasadena, Maryland • Austin, Texas

Conditions: Iron Deficiency Anemia, Pregnancy
Interventions: Ferric derisomaltose, Ferrous sulfate; Drug
Lead sponsor: Women and Infants Hospital of Rhode Island; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 8
States / cities: Birmingham, Alabama • Miami, Florida • Ann Arbor, Michigan + 4 more

Conditions: Healthy Volunteers
Interventions: AV-1, Placebo; Drug
Lead sponsor: AbViro LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Post-operative Pain
Interventions: IV Acetaminophen, Saline as placebo; Drug · Other
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: The Bronx, New York

Search by objective public record fields.

Double Simultaneous Uterotonic Agents Versus Single Agent Regimen to Prevent Early Postpartum Hemorrhage

DMID 23-0015; Lassa Fever CVD 1000

Ovarian Rejuvenation Using Platelet Rich Plasma (PRP) & Autologous Tissue Stromal Vascular Fraction (tSVF) and Cell Enriched tSVF

Intraosseous Vancomycin in Primary Total Hip Arthroplasty - Designing a Protocol

Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer

Delayed Renal Allograft Function and Furosemide Treatment

High-dose Erythropoietin for Asphyxia and Encephalopathy

Efficacy of IV Acetaminophen in Acute Post-Operative Pain Control in Laparoscopic Roux-en-Y Gastric Bypass Surgery (LRYGBP) Patients

Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy

Changes in Hemorrhage With Prophylactic Oxytocin for Dilation and Evacuation

Optimal Timing of Intercostal Nerve Blocks During Video-Assisted Thoracic Surgeries

7% Hypertonic Saline for Acute Bronchiolitis

Differential Gene Expression in Lung and Peripheral Blood After Inhaled Allergen Challenge

Study to Evaluate the Pharmacodynamic Effects of a Single Oral Dose of GS-0976 (NDI-010976) in Healthy Adult Subjects

Intravenous Fluid Therapy for the Treatment of Emergency Department Patients With Migraine Headache

A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis

SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma

Phase II Trial of Pentostatin in Steroid Refractory Acute Graft Versus Host Disease

Effect of Increased Free Fatty Acids on Leptin Function

A Study for Patients With Head and Neck Cancer

Maxigesic IV Phase 3 Bunionectomy Study

Intravenous Versus Oral Iron for Treating Iron-Deficiency Anemia in Pregnancy

A Study to Determine the Safety of AV-1, an Antibody Being Developed for Treatment of Dengue, in Healthy Volunteers

IV Acetaminophen for Acute Post Operative Pain in C-Section Patients